06:30 PM EST, 11/19/2025 (MT Newswires) -- CFRA, an independent research provider, has provided MT Newswires with the following research alert. Analysts at CFRA have summarized their opinion as follows:

According to an unconfirmed Bloomberg report, cancer screening and diagnostics firm EXAS may soon be acquired by medical device giant Abbott Laboratories. No indication was given as to a potential takeover price or offer terms, though we note that EXAS shares rose ~20% within a three-hour span, with significant trading volume, after the story broke around midday Wednesday. We note analyst speculation about a potential $100 per share price (~16% above Wednesday's close or ~40% above pricing before the report). As the market leader in colorectal cancer screening, EXAS's Cologuard product is widely utilized as an alternative to traditional colonoscopy, with the stool-based DNA test providing a less invasive option for patients, albeit with somewhat lower performance in detection. During Q3 2025, EXAS's Screening business, anchored by Cologuard, generated $666 million in revenue, up 22% Y/Y. The company has yet to generate a positive full-year profit, though 2025 is expected to mark an inflection point.